Cellebrite DI Ltd. Fundamental Analysis
Cellebrite DI Ltd. (CLBTW) shows weak financial fundamentals with a PE ratio of 52.60, profit margin of 14.48%, and ROE of 15.53%. The company generates $0.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CLBTW's fundamental strength across five key dimensions:
Efficiency Score
WeakCLBTW struggles to generate sufficient returns from assets.
Valuation Score
ModerateCLBTW shows balanced valuation metrics.
Growth Score
ModerateCLBTW shows steady but slowing expansion.
Financial Health Score
ExcellentCLBTW maintains a strong and stable balance sheet.
Profitability Score
ModerateCLBTW maintains healthy but balanced margins.
Key Financial Metrics
Is CLBTW Expensive or Cheap?
P/E Ratio
CLBTW trades at 52.60 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CLBTW's PEG of 0.31 indicates potential undervaluation.
Price to Book
The market values Cellebrite DI Ltd. at 7.42 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 30.90 times EBITDA. This signals the market has high growth expectations.
How Well Does CLBTW Make Money?
Net Profit Margin
For every $100 in sales, Cellebrite DI Ltd. keeps $14.48 as profit after all expenses.
Operating Margin
Core operations generate 12.76 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.53 in profit for every $100 of shareholder equity.
ROA
Cellebrite DI Ltd. generates $7.55 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cellebrite DI Ltd. generates strong operating cash flow of $137.36M, reflecting robust business health.
Free Cash Flow
Cellebrite DI Ltd. generates strong free cash flow of $125.97M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.62 in free cash annually.
FCF Yield
CLBTW converts 4.01% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
52.60
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.31
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How CLBTW Stacks Against Its Sector Peers
| Metric | CLBTW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 52.60 | 35.40 | Worse (Expensive) |
| ROE | 15.53% | 779.00% | Weak |
| Net Margin | 14.48% | -137241.00% (disorted) | Strong |
| Debt/Equity | 0.04 | 0.45 | Strong (Low Leverage) |
| Current Ratio | 1.53 | 3.37 | Neutral |
| ROA | 7.55% | 206.00% | Weak |
CLBTW outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cellebrite DI Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Growth, Innovation, High Beta
EPS CAGR
N/A
Industry Style: Growth, Innovation, High Beta
FCF CAGR
N/A
Industry Style: Growth, Innovation, High Beta